ARF4

Across TCGA pan-cancer cohorts, ARF4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARF4 data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARF4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARF4 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where ARF4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.397	1.000	.001	39	view →
LSCC	DFS	Median	II,III,IV	0.830	1.000	.003	25	view →
GBM	DFS	Median	All	0.296	0.443	.010	11	view →
PDAC	DFS	Median	III,IV	0.162	0.548	.002	9	view →
HNSC	DFS	Tertile	III,IV	0.919	0.683	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARF4–CCRCC (DFS)

Open the CCRCC breakdown →